Argus raised the firm’s price target on Alcon to $95 from $90 and keeps a Buy rating on the shares. The company has shown strong performance, leading to 15% constant currency sales growth in its Vision Care segment and 10% growth in its Surgical segment in the second quarter, the analyst tells investors in a research note. The firm is also raising its 2023 EPS view by 10c to $2.75 and its FY24 view by 15c to $3.15 while citing Alcon management having recently upgraded its outlook for revenue and earnings in recent quarters driven by the launch of new products and strength across its portfolio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALC:
- Alcon price target raised to CHF 90 from CHF 88 at Berenberg
- Alcon price target raised to CHF 88 from CHF 85 at Credit Suisse
- Alcon Stock (NYSE:ALC) Gained on Bullish Analysts’ Views
- Adobe upgraded, BorgWarner downgraded: Wall Street’s top analyst calls
- Alcon price target raised to $89 from $80 at Wells Fargo
Questions or Comments about the article? Write to editor@tipranks.com